The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response

Hepatology

Volumn 63, Issue 3, 2016, Pages 1056-1057

  Argo, Curtis K ^a   Ikura, Yoshihiro ^b   Lackner, Carolin ^c   Caldwell, Stephen H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Takatsuki   (Japan)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; FAT DROPLET; SONIC HEDGEHOG PROTEIN; ALPHA TOCOPHEROL; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN; VITAMIN;

CELL MIGRATION; CYTOSKELETON; DIGESTIVE TRACT PARAMETERS; HEPATOCELLULAR BALLOONING; LETTER; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE; ANIMAL; CAROTID ARTERY DISEASE; FATTY LIVER; FEMALE; GENETICS; HUMAN; LIVER; MALE; METABOLISM; PATHOLOGY;

ANIMALS; CAROTID ARTERY DISEASES; FATTY LIVER; FEMALE; HEDGEHOG PROTEINS; HUMANS; LIPASE; LIPOPROTEINS, VLDL; LIVER; MALE; MEMBRANE PROTEINS; NON-ALCOHOLIC FATTY LIVER DISEASE; VITAMIN E; VITAMINS;

EID: 84946097410     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28009     Document Type: Letter

References (18)

1. Guy CD, Suzuki A, Abdelmalek MF, Burchette JL, Diehl AM; NASH CRN. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity. Hepatology 2015;61:98-107.
2. Smagris E, BasuRay S, Li J, Huang Y, Lai KM, Gromada J, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 2015;61:108-118.
3. Hirsova P, Gores GJ. Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis. Hepatology 2015;61:15-17.
4. Boursier J, Diehl AM. Patatin-like phospholipase domain-containing protein 3 and liver disease: opportunities to unravel mechanisms underlying statistical associations. Hepatology 2015;61:18-20.
5. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-514.
6. Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 2015;61:515-525.
7. Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, et al. Hepatocellular ballooning in NASH. J Hepatol 2010;53:719-723.
8. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008;48:821-828.
9. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology 2006;43:506-514.
10. Welte MA, Cermelli S, Griner J, Viera A, Guo Y, Kim DH, et al. Regulation of lipid-droplet transport by the perilipin homolog LSD2. Curr Biol 2005;15:1266-1275.
11. Cairns SR, Peters TJ. Isolation of micro- and macro-droplet fractions from needle biopsy specimens of human liver and determination of the subcellular distribution of the accumulating liver lipids in alcoholic fatty liver. Clin Sci 1984;67:337-345.
12. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
13. Juluri R, Vuppalanchi R, Olson J, Unalp A, Van Natta ML, Cummings OW, et al. Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 2011;45:55-58.
14. Gawrieh S, Knoedler DM, Saeian K, Wallace JR, Komorowski RA. Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. Ann Diagn Pathol 2011;15:19-24.
15. Kleiner DE, Yah MM, Guy CD, Ferrell L, Cummings O, Contos MJ, et al. Creation of a continuous visual scale of ballooned hepatocytes in non-alcoholic fatty liver disease. Hepatology 2008;48(Suppl):815A.
16. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, Lavine J, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54:344-353.
17. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, Goodman Z. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874-1882.
18. Ratziu V. Starting the battle to control non-alcoholic steatohepatitis. Lancet 2014;385:922-924.